Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH S
暂无分享,去创建一个
R. Kaiser | J. Gatell | K. Ruxrungtham | D. Cooper | J. Rockstroh | W. Sugiura | A. Kelleher | S. Emery | A. Clarke | J. Amin | W. Belloso | R. Harrigan | S. Pett | J. Gill | P. Mallon | M. Losso | E. Tu | I. Woolley | T. Prazuck | M. Fisher | M. Wolff | D. Silk | A. Horban | J. Andrade-Villanueva | N. Porteiro | J. Sierra Madero | A. Clark | J. Arnaiz